Initiating and intensifying insulin therapy for type 2 diabetes: Why, When, and How

American Journal of Therapeutics

Volumn 16, Issue 1, 2009, Pages 56-64

  Cobble, Michael E ^a  

^a Canyons Medical Center   (United States)

Author keywords

Insulin; Insulin analogues; Oral antidiabetic drags; Type 2 diabetes

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLITAZONE DERIVATIVE; HUMALOG MIX; INNOLET; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; METFORMIN; NATEGLINIDE; PRAMLINTIDE; RECOMBINANT HUMAN INSULIN; REPAGLINIDE; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA; UNCLASSIFIED DRUG;

DRUG COST; DRUG DELIVERY SYSTEM; DRUG DOSE INCREASE; DRUG DOSE TITRATION; ELDERLY CARE; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HUMAN; INSULIN TREATMENT; LACTIC ACIDOSIS; LIFESTYLE MODIFICATION; MEDICAL EDUCATION; MEDICAL STAFF; NON INSULIN DEPENDENT DIABETES MELLITUS; NURSE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; WEIGHT GAIN;

BLOOD GLUCOSE; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 2; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; PRACTICE GUIDELINES AS TOPIC;

EID: 60249097663     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3181966bf0     Document Type: Review

References (50)

1. Lebovitz HE, Austin MM, Blonde L, et al. ACE/AACE consensus conference on the implementation of outpatient management of diabetes mellitus: consensus conference recommendations. Endocr Pract. 2006;12(Suppl 1): 6-12.
2. Centers for Disease Control and Prevention. National Diabetes Fact Sheet. 2005. Available at http://www.cdc.gov/diabetes/pubs/pdf/ndfs-2005.pdf. Accessed April 16, 2008.
3. American Diabetes Association. Economic costs of diabetes in the US in 2007. Diabetes Care. 2008;31:596-615.
4. UKPDS. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:854-865.
5. UKPDS. Intensive blood-glucose control with sulphony- lureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837-853.
6. Chao CC, Hsieh SC, Yang WS, et al. Glycemic control is related to the severity of impaired thermal sensations in type 2 diabetes. Diabetes Metab Res Rev. 2007;23:612-620.
7. Rossing P. Diabetic nephropathy: worldwide epidemic and effects of current treatment on natural history. Curr Diab Rep. 2006;6:479-483.
8. van den Berg E, Kessels RP, Kappelle LJ, et al. Type 2 diabetes, cognitive function and dementia: vascular and metabolic determinants. Drugs Today (Bare). 2006;42: 741-754.
9. Genuth S. Insights from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study on the use of intensive glycemic treatment to reduce the risk of complications of type 1 diabetes. Endocr Pract. 2006;12(Suppl 1):34-41.
10. Blonde L, Dempster J, Gallivan JM, et al. Reducing cardiovascular disease risk in patients with diabetes: a message from the National Diabetes Education Program. J Am Acad Nurse Pract. 2006;18:524-533.
11. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383-393.
12. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-412.
13. Shichiri M, Kishikawa H, Ohkubo Y, et al. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care. 2000; 23(Suppl 2):B21-B29.
14. Nathan DM, Cleary PA, Backhand JY, et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643-2653.
15. American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care. 2008;31(Suppl 1): S12-S54.
16. Hoerger TJ, Segel JE, Gregg EW, et al. Is glycemic control improving in US adults? Diabetes Care. 2008;31:81-86.
17. Ford ES, Li C, Little RR, et al. Trends in A1C concentrations among US adults with diagnosed diabetes from 1999 to 2004. Diabetes Care. 2008;31:102-104.
18. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007;13(Suppl 1): 1-68.
19. Jellinger PS, Davidson JA, Blonde L, et al. Road maps to achieve glycemic control in type 2 diabetes mellitus: ACE/AACE Diabetes Road Map Task Force. Endocr Pract. 2007;13:260-268.
20. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006;29:1963-1972.
21. Wright A, Burden AC, Paisey RB, et al. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care. 2002;25: 330-336.
22. Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med. 2007;147: 386-399.
23. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and metaanalysis. JAMA. 2007;298:194-206.
24. Hollander P, Ratner R, Fineman M, et al. Addition of pramlintide to insulin therapy lowers HbAlc in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets. Diabetes Obes Metab. 2003; 5:408-414.
25. Hirsch IB, Bergenstal RM, Parkin CG, et al. A real world approach to insulin therapy in primary care practice. Clin Diabetes. 2005;23:78-86.
26. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427-2443.
27. Trachtenbarg DE. Diabetic ketoacidosis. Am Fam Physician. 2005;71:1705-1714.
28. Clement S. Better glycemic control in the hospital: beneficial and feasible. Cleve Clin J Med. 2007;74:111- 112, 114-120.
29. Garg SK, Ulrich H. Achieving goal glycosylated hemoglobin levels in type 2 diabetes mellitus: practical strategies for success with insulin therapy. Insulin. 2006; 1:109-121.
30. Horvath K, Jeitler K, Berghold A, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2007;CD005613.
31. Home P, Kurtzhals P. Insulin detemir: from concept to clinical experience. Expert Opin Pharmacother. 2006;7: 325-343.
32. Heise T, Nosek L, Ronn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes. 2004;53:1614-1620.
33. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26:3080-3086.
34. Klein O, Lynge J, Endahl L, et al. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab. 2007;9: 290-299.
35. Vazquez-Carrera M, Silvestre JS. Insulin analogues in the management of diabetes. Methods Find Exp Clin Pharmacol. 2004;26:445-61.
36. Gough SC. A review of human and analogue insulin trials. Diabetes Res Clin Pract. 2007;77:1-15.
37. Meneghini L, Koenen C, Weng W, et al. The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes- results of the randomized, controlled PREDICTIVE 303 study. Diabetes Obes Metab. 2007;9:902-913.
38. Brunton S, Carmichael B, Funnell M, et al. Type 2 diabetes: the role of insulin. J Earn Pract. 2005;54:445-452.
39. Raskin P, Allen E, Hollander P, et al. Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2005;28:260-265.
40. Lingvay I, Kaloyanova PF, Adams-Huet B, et al. Insulin as initial therapy in type 2 diabetes: effective, safe, and well accepted. J Investig Med. 2007;55:62-68.
41. Rosenstock J, Ahmann AJ, Colon G, et al. Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents. Diabetes Care. 2008;31:20-25.
42. Cefalu C, Cefalu W. The older patient with type 2 diabetes: special considerations and management with insulin. Ann Long-Term Care: Clin Care Aging. 2007;14: 17-24.
43. Ahmann AJ. Guidelines performance measures for diabetes. Am J Manag Care. 2007;13(Suppl 2):S41-S46.
44. Royal College of Nursing Monograph. Starting insulin treatment in adults with type 2 diabetes. 2004. Available at http://www.rcn.org.uk/-data/assets/pdf- file/0009/78606/002254.pdf. Accessed April 16, 2008.
45. Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005;28:2673-2679.
46. Brunton SA, Davis SN, Renda SM. Overcoming psychological barriers to insulin use in type 2 diabetes. Clin Cornerstone. 2006;8(Suppl 2):S19-S26.
47. Stewart K. Insulin delivery devices. J Pharm Pract. 2004;17: 20-28.
48. Flood T. Advances in insulin delivery systems and devices: beyond the vial and syringe. Insulin. 2006;1: 99-108.
49. Da Costa S, Brackenridge B, Hicks D. A comparison of insulin pen use in the United States and the United Kingdom. Diabetes Educ. 2002;28:52-56, 59-60.
50. Graff MR, McClanahan MA. Assessment by patients with diabetes mellitus of two insulin pen delivery systems versus a vial and syringe. Clin Ther. 1998;20: 486-496.